首页> 外国专利> NEUREGULIN BASED COMPOSITIONS AND USES THEREOF FOR PREVENTING OR TREATING MYOCARDIAL ISCHEMIA-REPERFUSION INJURY

NEUREGULIN BASED COMPOSITIONS AND USES THEREOF FOR PREVENTING OR TREATING MYOCARDIAL ISCHEMIA-REPERFUSION INJURY

机译:基于神经胶质的组合物及其在预防或治疗心肌缺血再灌注损伤中的用途

摘要

The present invention elates to the applications of neuregulin in the preparation of drugs for preventing, treating or delaying the ischemia-reperfusion injury (IRI) in mammals, particularly in humans. In particular, the present invention provides the neuregulin based compositions and methods for preventing, treating or delaying the myocardial ischemia-reperfusion injury. Specifically, although it has been shown in cytological experiments, animal studies and clinical trials that neuregulin can improve the cytoskeleton structure of myocytes and cardiac function, it is still unknown whether neuregulin has effects on the myocardial ischemia-reperfusion injury. The present invention proves that neuregulin reduces the infarction size in the rat IRI model, which indicates that neuregulin can be used for preventing, treating or delaying the myocardial ischemia-reperfusion injury
机译:本发明涉及神经调节蛋白在制备用于预防,治疗或延迟哺乳动物特别是人类的缺血-再灌注损伤(IRI)的药物中的应用。特别地,本发明提供了基于神经调节蛋白的组合物和用于预防,治疗或延迟心肌缺血-再灌注损伤的方法。具体而言,尽管在细胞学实验,动物研究和临床试验中已表明神经调节蛋白可以改善心肌细胞的骨架结构和心脏功能,但神经调节蛋白是否对心肌缺血-再灌注损伤有影响仍是未知的。本发明证明了神经调节蛋白减少了大鼠IRI模型中的梗塞面积,这表明神经调节蛋白可以用于预防,治疗或延迟心肌缺血-再灌注损伤。

著录项

  • 公开/公告号EP2528616B1

    专利类型

  • 公开/公告日2017-09-27

    原文格式PDF

  • 申请/专利权人 ZENSUN (SHANGHAI) SCIENCE & TECHNOLOGY CO. LTD.;

    申请/专利号EP20110736605

  • 发明设计人 ZHOU MINGDONG;

    申请日2011-01-11

  • 分类号A61K38/18;A61P9/10;

  • 国家 EP

  • 入库时间 2022-08-21 14:06:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号